News & Events about Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the notes) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act...
Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the notes) in a private offering to qualified institutional buyers pursuant to Rule 144A...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023. The companys preliminary unaudited financial results for the first quarter of 2023 include: Approximately $31.5 million of total revenue...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2023, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,950 shares of common stock and 12,960 restricted stock units (RSUs) to five...
Latest Ratings for MIRM
DateFirmActionFromTo Mar 2022Raymond JamesMaintainsStrong Buy Jan 2022SVB LeerinkMaintainsOutperform Jan 2022Raymond JamesMaintainsStrong Buy
View More Analyst Ratings for MIRM
View the Latest Analyst Ratings
read more...